menu
    • menu
    [{"orgOrder":0,"company":"Eckert & Ziegler Strahlen","sponsor":"Ariceum Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Peptide","year":"2024","type":"Agreement","leadProduct":"177Lu-Satoreotide Tetraxetan","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Eckert & Ziegler Strahlen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eckert & Ziegler Strahlen \/ Ariceum Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Eckert & Ziegler Strahlen \/ Ariceum Therapeutics"},{"orgOrder":0,"company":"Eckert & Ziegler Strahlen","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2024","type":"Partnership","leadProduct":"225-Ac PSMA-RADmAb","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Eckert & Ziegler Strahlen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eckert & Ziegler Strahlen \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Eckert & Ziegler Strahlen \/ Telix Pharmaceuticals"},{"orgOrder":0,"company":"Eckert & Ziegler Strahlen","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2023","type":"Agreement","leadProduct":"PNT2001","moa":"Alpha radiation ionising","graph1":"Oncology","graph2":"Preclinical","graph3":"Eckert & Ziegler Strahlen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eckert & Ziegler Strahlen \/ Point Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Eckert & Ziegler Strahlen \/ Point Biopharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Eckert & Ziegler Strahlen

    Menu

    Eckert & Ziegler Strahlen

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Eckert & Ziegler Strahlen

    Germany arrow
    Interphex
    Not Confirmed

    Eckert & Ziegler Strahlen

    Germany arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : 177Lu-Satoreotide Tetraxetan

    Therapeutic Area : Oncology

    Study Phase : Phase I

    Sponsor : Ariceum Therapeutics

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Ariceum, Eckert Sign Agreement for Radiotherapeutics Cancer Treatments

    Details : Eckert & Ziegler will supply Ariceum with n.c.a. Ac-225 and Lu-177 used to radiolabel Ariceum's proprietary lead radiopharmaceutical drug SS0110 (satoreotide) targeting hard-to-treat cancers.

    Product Name : 177Lu-SSO110

    Product Type : Peptide

    Upfront Cash : Undisclosed

    December 05, 2024

    Lead Product(s) : 177Lu-Satoreotide Tetraxetan

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Sponsor : Ariceum Therapeutics

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Eckert & Ziegler Strahlen

    Germany arrow
    Interphex
    Not Confirmed

    Eckert & Ziegler Strahlen

    Germany arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : 225-Ac PSMA-RADmAb

    Therapeutic Area : Oncology

    Study Phase : Phase I

    Sponsor : Telix Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology

    Details : The partnership aims to provide Telix with both an additional commercial source of 225Ac and access to a platform technology for use in the development of next generation TATs, including TLX592.

    Product Name : TLX592

    Product Type : Radiolabelled Compounds

    Upfront Cash : Undisclosed

    November 13, 2024

    Lead Product(s) : 225-Ac PSMA-RADmAb

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Sponsor : Telix Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Partnership

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Eckert & Ziegler Strahlen

    Germany arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed

    Eckert & Ziegler Strahlen

    Germany arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : PNT2001

    Therapeutic Area : Oncology

    Study Phase : Preclinical

    Sponsor : Point Biopharma

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Eckert & Ziegler to Supply POINT Biopharma with Actinium-225

    Details : Under the agreement, Eckert & Ziegler will provide predetermined amounts of GMP grade Ac-225 to POINT for use in the development of POINT’s pipeline of next generation Ac-225-based radioligands, including PSMA-targeted PNT2001 program.

    Product Name : PNT2001

    Product Type : Radiolabelled Compounds

    Upfront Cash : Undisclosed

    April 04, 2023

    Lead Product(s) : PNT2001

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Sponsor : Point Biopharma

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth